Clinical Research Directory
Browse clinical research sites, groups, and studies.
QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
Sponsor: Qilu Pharmaceutical Co., Ltd.
Summary
This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.
Official title: Evaluation of Efficacy and Safety of QLC7401 Monotherapy in Participants With Non-familial Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
510
Start Date
2026-03-05
Completion Date
2028-02-28
Last Updated
2026-03-02
Healthy Volunteers
No
Interventions
QLC7401
QLC7401 Injection
Placebo
Placebo matching QLC7401 in appearance and administration.